Meta analysis using the most serious outcome reported shows 0% [-9‑9%] lower risk, without reaching statistical significance.
4 studies from 4 independent teams in 4 countries show statistically significant improvements.
Concerns have been raised over potential harm with the use of ibuprofen for COVID-19 Day due to the suppression of beneficial immune and inflammatory responses during early infection, ACE2 upregulation, and delaying further care. There is limited clinical data currently, especially with regard to acute usage at onset of infection, however current results suggest harm with early treatment and benefit with late treatment.
No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments are significantly more effective.
All data to reproduce this paper and sources are in the appendix.
Covid Analysis et al., Apr 2024, preprint, 1 author.
